29 January 2025
In September 2025, the Russian personalized mRNA vaccine will be used in an experimental mode. The Ministry of Health’s permission is expected in August, but the plan is still awaiting approval.
Clinical trials of the new drug will start with patients suffering from melanoma and small cell lung cancer. At the same time, the therapy will be available, including to those who have already undergone certain stages of treatment.
This drug is the product of a collaborative effort among experts from the Gamaleya Center, the Herzen Moscow Oncology Research Institute, and the Blokhin National Medical Research Center of Oncology. The technology is based on an mRNA platform that provides a high concentration of the target antigen in cells.
The development is protected by Russian patents and is an independent technological solution. The state will incur a cost of approximately 300,000 rubles for each individual cancer vaccine, yet patients will receive this life-saving treatment at no charge.
PrintMerry Christmas and Happy New Year!
28 December 2024
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
Enhancing spectroscopy analysis with machine learning
03 February 2025
The production of new Russian “super antibiotic” to begin in Novosibirsk
03 February 2025
A Russian company has started producing 4 veterinary vaccines
31 January 2025
The government held its first meeting on the “New technologies for preserving health” project
31 January 2025